▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #62 by analyst upside · 2026-06-27
ESLA
Estrella Immunopharma, Inc.
Healthcare · Market Cap $42M · P/E 0x
ANALYST PRICE TARGET
+1121.0%
implied upside to consensus target
Current Price $0.98
Consensus Target $12.0
Bull Target $12.0
Bear Target $12.0
Analysts Covering 1
ANALYST CONSENSUS — BUY
Strong Buy
0
Buy
1
Hold
0
Sell
0
52-Week Low $0.78
52-Week High $3.15
YTD Return -29.3%
FUNDAMENTALS
Market Cap $42M
P/E Ratio (TTM) N/A
Forward P/E -3.1x
EPS (TTM) $-0.34
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.78
52-Week High $3.15
Current Price $0.98
Bear Target $12.0
Bull Target $12.0
● Now $0.98 ● Target $12.0
TRADING DATA
Avg Volume 80K
YTD Return -29.3%
Analyst Count 1
Consensus Buy
Upside to Target +1121.0%
Last Updated 2026-06-27

ANALYST SUMMARY

Estrella Immunopharma, Inc. (ESLA) is currently trading at $0.98 with a Wall Street consensus price target of $12.0, implying potential upside of 1121.0% over the next 12 months. 1 analysts currently cover ESLA, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $12.0, while the most cautious has a target of $12.0.

ESLA operates in the Healthcare sector with a market capitalisation of $42M. The stock is down 29.3% year-to-date and is currently trading near the lower end of its 52-week range of $0.78 – $3.15.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

PSTV +757.1%
Plus Therapeutics, Inc.
$29M · P/E 0.2x · Buy
DWTX +748.5%
Dogwood Therapeutics, Inc.
$55M · P/E 1.4x · Strong Buy
ETST +566.7%
Earth Science Tech, Inc.
$43M · P/E 15.0x · Hold
VXRT +488.2%
Vaxart, Inc.
$123M · P/E 3.2x · Buy
AGEN +411.6%
Agenus Inc.
$126M · P/E 1.4x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ESLA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

D. Boral Capital — Reiterated
Buy → Buy 2026-02-09 32% win rate (25 calls)
D. Boral Capital — Reiterated
Buy → Buy 2026-01-28 32% win rate (25 calls)
D. Boral Capital — Reiterated
Buy → Buy 2025-11-03 32% win rate (25 calls)
D. Boral Capital — Reiterated
Buy → Buy 2025-08-12 32% win rate (25 calls)
D. Boral Capital — Reiterated
Buy → Buy 2025-06-03 32% win rate (25 calls)
D. Boral Capital — Reiterated
Buy → Buy 2025-05-29 32% win rate (25 calls)
D. Boral Capital — Reiterated
Buy → Buy 2025-02-21 32% win rate (25 calls)
D. Boral Capital ● Initiated
Buy 2025-02-18 32% win rate (25 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →